Aidoc, an Israeli-founded clinical AI company, said it has raised $150 million in Series E funding led by Growth Equity at Goldman Sachs Alternatives, bringing its total funding to more than $500 million.
The round included participation from General Catalyst, SoftBank Vision Fund 2 and NVentures, Nvidia’s venture capital arm. It comes less than a year after a growth round led by General Catalyst and Square Peg, reflecting growing demand for enterprise-scale clinical AI in hospitals, the company said.
Diagnostic errors and delays contribute to at least 400,000 deaths each year in the United States, according to Aidoc, amid rising imaging volumes, workforce shortages and increasing clinical complexity. While AI has long been seen as a tool to reduce that burden, many products have focused on single use cases, limiting their broader impact.
Aidoc said the market is now shifting toward AI systems deployed across entire health networks. Foundation models have made that transition technically possible by enabling broader coverage across medical conditions and imaging types from a single architecture, but bringing those systems into regulated, real-world care remains complex.
The company developed its own clinical foundation model, CARE, and deployed it through its enterprise platform, aiOS. Earlier this year, CARE received what Aidoc described as a landmark first clearance from the U.S. Food and Drug Administration for a comprehensive double-digit foundation model-based triage system in clinical imaging.
Aidoc said it analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals.
“By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error,” said Elad Walach, Aidoc’s co-founder and CEO. “We feel a deep responsibility to deploy CARE safely and at scale across health systems.”
Walach said the new funding would help expand disease coverage and advance end-to-end AI across CT and X-ray imaging, including workflows “from pixel to draft report” within two years.
As clinical AI moves toward system-wide deployment, governance and regulatory oversight have become central issues for hospitals. Aidoc said large health systems require not only advanced technology, but also accountability and controls to operate AI safely in clinical care.
“Aidoc pairs advanced technology with regulatory rigor in a way that few companies have achieved,” said Christian Resch, partner at Growth Equity at Goldman Sachs Alternatives. “Health systems consistently describe tangible results, including improved radiology efficiency, shorter lengths of stay and measurable financial returns.”
The company said the new capital will support further development of CARE, expansion into additional clinical indications and new capabilities such as automated draft imaging reports. It will also fund broader global deployment of Aidoc’s aiOS platform, which is designed to help hospitals centralize the deployment, management and governance of multiple AI tools.
Aidoc says its technology has analyzed more than 110 million patient cases and supports clinical decision-making for about 70 million patients annually.